Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma
Status:
Recruiting
Trial end date:
2021-04-30
Target enrollment:
Participant gender:
Summary
Up to 31 subjects diagnosed with oral squamous cell carcinoma will receive one application of
a permeation enhancer and 2, 3, or 5 treatment applications of a Cisplatin drug-loaded patch
to the tumor site at each of 4 treatment visits. These 4 treatment visits will be scheduled
to occur during the 3 weeks prior to the standard of care tumor resection.
Funding Source: FDA OOPD